- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 02.10. | This week in charts: Kodiak's big comeback and Hengrui's dealmaking | ||
| 01.10. | 3 takeaways from a European obesity scientific meeting | ||
| 01.10. | Sanofi, Regeneron broaden alliance to find their next Dupixent | ||
| 01.10. | HHS kicks off new programs to speed clinical trials as Chinese competition looms | ||
| 01.10. | 5 FDA decisions to watch in the fourth quarter of 2026 | ||
| 30.09. | Bristol Myers trial revisions shake confidence in new class of fibrosis drugs | ||
| 30.09. | FDA starts review of Roche's multiple sclerosis pill | ||
| 30.09. | PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval | ||
| 29.09. | Beam sues 2 biotechs, alleging theft of base editing trade secrets | ||
| 29.09. | Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill | ||
| 29.09. | UniQure tumbles with latest data for Huntington's gene therapy | ||
| 29.09. | ai3Bio, built from two biotechs, pursues a different path to an 'immune reset' | ||
| 29.09. | AstraZeneca invests $2B in Summit, gaining 'seat at the table' for PD-1/VEGF drug push | ||
| 28.09. | Kodiak skyrockets on positive study data for 2 eye drugs | ||
| 28.09. | An 'off-the-shelf' CAR-T therapy from Adicet shows promise against lupus | ||
| 28.09. | Merck, Daiichi end plans to seek speedy approval of lung cancer ADC | ||
| 28.09. | Kids shouldn't have to organize childhood around medicine | ||
| 28.09. | Breakthrough therapies still need builders | ||
| 25.09. | This week in charts: Novo's rise and fall and AI biotechs' big haul | ||
| 25.09. | Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer's data | ||
| 25.09. | RNAi drug specialist ADARx raises $446M IPO | ||
| 24.09. | Grail multicancer detection test wins FDA advisers' backing | ||
| 24.09. | FDA nominee Overton parries vaccine questions at Senate hearing | ||
| 24.09. | Merck reveals study success, and possible safety worries, for eye drug hopeful | ||
| 24.09. | Lilly's latest China drug deal; Immunovant's setback in lupus |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.